Prosecution Insights
Prosecution Insights
Tech Center 2800 • Art Units: 1617 1622 1625 1627 2834
This examiner grants 40% of resolved cases
Layla Soroush has an allowance rate of 40.5 percent based on 889 resolved cases. The median time to allowance is 1380 days. In Art Unit 1617, the interview lift is 43.4 percent. This 43.4 percent lift is higher than the 40.5 percent baseline allowance rate in Tech Center 2800.
The 43.4 percent interview lift suggests that interviews are an effective strategy for this examiner. Practitioners should prioritize direct communication to improve the 40.5 percent baseline. The 1380-day median pendency is a key metric for managing client expectations. With 889 resolved cases, these figures provide a reliable statistical foundation.
The 40.5 percent allowance rate and the 43.4 percent interview lift are the primary data points for strategy. In Art Unit 1617, the 1380-day timeline is a factor for long-term planning. These metrics help define the expected path for applications.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16446718 | Process For Formation of Emulsion Containing Liquid Crystal Structure | Final Rejection | Kenvue Brands LLC |
| 17854066 | PHOTODYNAMIC THERAPY METHOD FOR SKIN DISORDERS | Non-Final OA | Sun Pharmaceutical Industries, Inc. |
| 18952934 | NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES | Non-Final OA | R.J. Reynolds Tobacco Company |
| 18861037 | TOBACCO ALKALOID INSECT REPELLENT IN PLANTS | Non-Final OA | Philip Morris Products S.A. |
| 17780851 | COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASES CAUSED BY GENETIC MUTATION COMPRISING FERULIC ACID AND ANALOGS THEREOF | Final Rejection | Daegu Gyeongbuk Institute of Science and Technology |
| 18711955 | OIL-IN-WATER EMULSION COSMETIC | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18253140 | METHOD OF TREATMENT OF PAIN THROUGH BUCCAL ADMINISTRATION OF FLUNIXIN | Final Rejection | Intervet Inc. |
| 19094303 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | Final Rejection | Xenon Pharmaceuticals Inc. |
| 18848646 | METHODS OF POTENTIATING TEMOZOLOMIDE ACTIVITY AGAINST GLIOBLASTOMA CELLS | Non-Final OA | University of Cincinnati |
| 17534888 | SHIKIMATE ANALOGUES AND METHODS OF USE | Final Rejection | The Board of Regents of the University of Oklahoma |
| 18245019 | TOPICAL TREATMENT OF VITILIGO | Non-Final OA | INCYTE CORPORATION |
| 17611891 | OIL-IN-WATER MACROEMULSION | Non-Final OA | SYMRISE AG |
| 17997515 | FAST-ACTING TOPICAL ANESTHETIC FORMULATIONS | Final Rejection | Achelon, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy